Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage

Area of Science:

• Immunology
• Virology
• Therapeutics

Background:

• Successful HIV-1 prevention and therapy necessitate broad coverage of global and within-host viral diversity.
• Broadly neutralizing antibodies (bNAbs) offer a promising avenue due to their potent and complementary activities.

Approach:

• Reviewing the principles and applications of bNAb combination and multispecific therapeutics.
• Analyzing clinical trial data, including the Antibody Mediated Prevention (AMP) trials, to assess neutralization potency and breadth requirements.
• Discussing how bNAb complementarity in neutralization profiles and resistance mutation coverage can address stringent therapeutic demands.

Key Points:

• The Antibody Mediated Prevention (AMP) trials highlight the high neutralization potency and breadth required for effective bNAb-mediated HIV-1 prevention.
• Therapeutic inhibition of diverse within-host HIV-1 quasispecies may demand even higher neutralization capabilities.
• Complementarity among bNAbs is crucial for overcoming these stringent requirements.

Conclusions:

• Next-generation bNAb-based combination or multispecific therapeutics must leverage component bNAb complementarity.
• Maximizing potency and breadth through strategic bNAb combinations is essential for clinical success in HIV-1 prevention and treatment.